Log in

OTCMKTS:PHGUF - Pharming Group Stock Price, Forecast & News

-0.07 (-6.67 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $0.98
50-Day Range
MA: $1.29
52-Week Range
Now: $0.98
Volume10,300 shs
Average Volume10,253 shs
Market Capitalization$613.36 million
P/E Ratio16.33
Dividend YieldN/A
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Read More
Pharming Group logo

Industry, Sector and Symbol

Industry Tobacco products



Sales & Book Value

Annual Sales$189.30 million



Market Cap$613.36 million
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHGUF and its competitors with MarketBeat's FREE daily newsletter.

Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

How has Pharming Group's stock been impacted by COVID-19 (Coronavirus)?

Pharming Group's stock was trading at $1.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHGUF shares have decreased by 27.4% and is now trading at $0.98. View which stocks have been mosted impacted by Coronavirus.

When is Pharming Group's next earnings date?

Pharming Group is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Pharming Group.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) posted its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01. View Pharming Group's earnings history.

Has Pharming Group been receiving favorable news coverage?

News coverage about PHGUF stock has trended very negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pharming Group earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutPharming Group.

Who are some of Pharming Group's key competitors?

What other stocks do shareholders of Pharming Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharming Group investors own include GALAPAGOS NV/S (GLPG), ArcelorMittal (MT), Net Element (NETE), Pieris Pharmaceuticals (PIRS), Bausch Health Companies (BHC), BIOLINERX LTD/S (BLRX), TIGENIX/S (TIG), Cellectis (CLLS), Accsys Technologies (AXS) and Powerflute Oyj (POWR).

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Dr. Sijmen de Vries M.D., MBA, Chairman of Management Board & CEO (Age 60)
  • Mr. Robin Wright BA (Oxon), FCA., CFO & Member of Management Board (Age 55)
  • Dr. Bruno M. L Giannetti, COO & Member of Management Board (Age 67)
  • Dr. Pericles Calias, Chief Scientific Officer (Age 51)
  • Ms. Anne-Marie de Groot, Sr. VP of Organisational Devel. (Age 38)

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $0.98.

How big of a company is Pharming Group?

Pharming Group has a market capitalization of $613.36 million and generates $189.30 million in revenue each year. The biotechnology company earns $40.55 million in net income (profit) each year or $0.06 on an earnings per share basis. Pharming Group employs 183 workers across the globe. View additional information about Pharming Group.

What is Pharming Group's official website?

The official website for Pharming Group is http://www.pharming.com/.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-71-524-7400 or via email at [email protected]

MarketBeat Community Rating for Pharming Group (OTCMKTS PHGUF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote "Outperform" if you believe PHGUF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHGUF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel